Celcuity (CELC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting is scheduled for May 14, 2026, to vote on director elections, auditor ratification, executive compensation, a new stock incentive plan, and an amended employee stock purchase plan.
Shareholders of record as of March 17, 2026, are entitled to vote, with 48,336,675 shares outstanding.
Proxy materials are available online, and voting can be done by mail, phone, or internet.
Voting matters and shareholder proposals
Proposals include electing eight directors, ratifying Boulay PLLP as auditor, approving executive compensation (say-on-pay), adopting the 2026 Stock Incentive Plan, and amending the 2017 Employee Stock Purchase Plan.
The board recommends voting FOR all proposals.
Shareholder proposals and director nominations for the 2027 meeting must comply with advance notice bylaws.
Board of directors and corporate governance
The board consists of eight nominees, with a majority qualifying as independent under Nasdaq rules.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board has adopted codes of ethics, an anti-bribery policy, and a policy prohibiting insider trading and hedging.
Family relationships exist between two executive officers (brother-in-law relationship).
Latest events from Celcuity
- FDA approval, strong trial data, and robust cash position support late Q3 launch and growth.CELC
Q2 2026 - REVTORPYK delivers best-in-class efficacy for HR+/HER2- breast cancer with strong market potential.CELC
Corporate presentation - FDA approved REVTORPYK for HR+/HER2-, PIK3CA wild-type advanced breast cancer; launch late Q3 2026.CELC
FDA announcement - Gedatolisib doubled PFS and set new efficacy benchmarks, with major regulatory milestones ahead.CELC
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Gedatolisib's phase III data show doubled PFS, supporting its potential as a new breast cancer standard.CELC
Jefferies Global Healthcare Conference 2026 - Gedatolisib regimens doubled PFS and set new efficacy benchmarks in advanced breast cancer.CELC
Study result - Positive Phase 3 data and FDA Priority Review set stage for 2026 launch; net loss at $52.8M.CELC
Q1 2026 - Key votes include director elections, auditor ratification, and approval of equity plans.CELC
Proxy filing - Strong Phase 3 data and $455M cash position support NDA submission and future commercialization.CELC
Q3 2025